Abstract The mucosal surfaces of the respiratory, gastrointestinal and urogenital tracts are covered by a layer of epithelial cells that are responsible for sensing and promoting a host immune response in order to establish the limits not only for commensal microorganisms but also for foreign organisms or particles. This is a remarkable task as the human body represents a composite of about 10 trillion human-self cells plus non-self cells from autochthonous or indigenous microbes that outnumber human cells 10:1. Hence, the homeostasis of epithelial cells that line mucosal surfaces relies on a fine-tuned immune system that patrols the boundaries between human and microbial cells. In the case of the intestine, the epithelial layer is composed of at least six epithelial cell lineages that act as a physiological barrier in addition to aiding digestion and the absorption of nutrients, water and electrolytes. In this review, we highlight the immense role of the intestinal epithelium in coordinating the mucosal innate immune response.
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Keeping the boundaries
As a barrier, the intestinal mucosa is well organized with absorptive enterocytes forming a layer of columnar-shaped cells or microvillus epithelium. This layer separates the intestinal lumen (mucosal) from the sub-epithelial lamina propria or basolateral domain (serosal) in which the mucosal immune cells reside. Moreover, a mucus layer covers the intestinal lumen, further restricting any contact between microorganisms and epithelial cells. This mucus layer is composed of mucin glycoproteins and trefoil peptides that are secreted by goblet cells located in both the villus and crypt epithelium of the entire intestinal tract. Humans possess at least 18 mucin-type glycoproteins. MUC2 is the predominant component of the mucin layer found in both the small and large bowel; in addition, intestinal trefoil factor 3 (TFF3) is co-expressed with MUC2. A wealth of evidence suggests that the mucin/ trefoil layer protects the intestinal epithelium from luminal pathogens and bacterial toxins and, at the same time, promotes wound repair (Kindon et al. 1995; de Repentigny et al. 2000 ; Kalabis et al. 2006) . Experiments in mice, for example, have shown that the absence of MUC2 expression is associated with rapid weight loss and enhanced mortality (Bergstrom et al. 2010) . Moreover, a comparison of patients suffering from inflammatory bowel disease (IBD) with healthy controls has provided evidence of a thinning of the mucus layer associated with augmentation of Streptococcus in Crohn's disease (CrD) and of Lactobacillus in ulcerative colitis (Fyderek et al. 2009 ), increased villous injury (Sharpe et al. 2010 ) and heightened infiltration of bacteria and inflammatory cells (Corazziari 2009) . These examples illustrate the important role that the mucus layer plays in forming a protective barrier to the lining of epithelial cells. Immunoglobulin A (IgA) offers another protective strategy that thwarts pathogen invasion to the intestinal epithelium. Undifferentiated crypt enterocytes secrete IgA into the intestinal lumen via the polymeric immunoglobulin receptor (pIgR; Mostov 1994) . Inside the epithelial cell, IgA can deactivate bacterial lipoproteins. Once in the lumen, IgA binds to the mucus layer located above the epithelial surface, where it aids in inhibiting the permeability and adherence of microorganisms and also neutralizes their toxins. Therefore, IgA plays an important role in maintaining the balance between the host and its indigenous bacteria or incoming pathogens by limiting their localization to the lumen (Apodaca et al. 1991) . Indeed, IgA represents the most abundant immunoglobulin found in the gut.
Furthermore, a wide range of antimicrobial peptides (AMPs), inflammatory mediators and signaling molecules are secreted by Paneth cells, which also assist in the maintenance of microbial homeostais within the gastrointestinal (GI) tract (Keshav 2006) . AMPs are cationic molecules produced to defend the host against insult by microbial pathogens. These molecules act as lytic enzymes that disturb the microbial cell membrane structure and/or its function (Ganz 1999) . At least three primary AMPs are expressed in the gut: defensins, lyzozymes and cathelicidins.
Defensins represent the predominant family of AMPs in mammals and possess a wide spectrum of antimicrobial activity (even at micromolar concentrations) against bacteria, fungi and some enveloped viruses. AMPs attach to the microbial membrane and disrupt it by forming a pore that leads to the efflux of ions and nutrients. Three types of human defensins have been identified and these differ with respect to the arrangement of their cysteine residues and the organization of their disulfide bridges: (1) α-defensins are mainly expressed in neutrophils and natural killer (NK) cells but are also found in granules of Paneth cells within the small intestine (Ouellette and Selsted 1996) ; (2) β-defensins are produced by numerous epithelial (Diamond and Bevins 1998; Fehlbaum et al. 2000) and nonepithelial (Garcia et al. 2001) cells; and (3) non-human θ-defensins are found in the granules of leukocytes (Tang et al. 1999 ) and bone marrow (Leonova et al. 2001 ) of the rhesus macaque.
The role of α-defensins in GI mucosal immunity has been previously documented for human α-defensin-5 (HD-5) by using transgenic mice (Wilson et al. 1999; Vaishnava et al. 2008) . Salzman et al. (2003) have found that the expression of HD-5 in transgenic mice is associated with resistance to orally administered Salmonella enterica serovar Typhimurium. In this study, transgenic mice recover following an initial onset of illness (12 h post-infection), whereas wildtype mice present 100% mortality after 24 h of infection. Moreover, the titer of Salmonella typhimurium recovered from wild-type mice is three log-fold greater than that recovered from transgenic mice (Salzman et al. 2003) . Interestingly, α-defensins are released exclusively by Paneth cells, which primarily reside in the small intestine and yet this protein can be found at relevant concentrations in the lumen of the distal colon, suggesting that it can resist degradation/proteolysis all the way through the intestine, thus emphasizing its role as a key player in colonic mucosal immunity (Mastroianni and Ouellette 2009 ).
Deficiency of α-defensin activity in patients with inflamed intestine is associated with not only tolerance to pathogens but also tolerance to indigenous intestinal microbiota (Duchmann et al. 1995; Salzman et al. 2007 ). This suggests that some primary defect in antibacterial α-defensins might lead to chronic inflammation. More recently, Salzman and collaborators (2010) have performed an extensive analysis on the changes that occur within the intestinal microbiota when comparing homozygous with heterozygous strains of transgenic mice encoding human Paneth cell α-defensin 5 (DEFA5). This team of investigators has found that mice lacking α-defensins show a significant increase in Firmicutes while at the same time exhibiting a decrease in Bacteroidetes as compared with mice over-expressing α-defensin. This finding implies that α-defensins, specifically DEFA5, play a fundamental role in altering the bacterial composition of the intestinal microbiota .
β-Defensins are antimicrobial peptides that reside at the epithelial surface and are involved in host defense against both bacteria and fungi. These defensins are continuously expressed throughout the GI tract, where they play a role in controlling the microbial population. For example, human β-defensin 1 (HBD1) is constitutively expressed by epithelial cells in the small intestine (Zhao et al. 1996) and is effective in eradicating Escherichia coli and S. typhimurium (Schröder 1999; De Smet and Contreras 2005) . Other human β-defensins, such as HBD2 and HBD3, are widely expressed within the epithelium of various tissues including the intestine. These β-defensins have antimicrobial activity against Gram-negative bacteria (E. coli and P. aeruginosa), several Gram-positive bacteria (Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus carnosus, multiresistant S. aureus strains and even the vancomycinresistant Enterococcus faecium) and yeasts (Candida albicans, Saccharomyces cerevisiae and Malassezia furfur; Jia et al. 2001) .
β-Defensins also trigger the activation and degranulation of mast cells, liberating histamine and prostaglandin D 2 (Bensch et al. 1995) . Increased levels of histamine have been associated with CrD (Knutson et al. 1990 ) and with ulcerative colitis (Raithel et al. 1995) , raising the possibility that the active involvement of histamine in the pathogenesis of these diseases results from the action of β-defensins on mast cells degranulation.
Lyzozymes and cathelicidins are additional AMPs that reside within the intestinal niche. Lysozymes represent mureinolytic enzymes that are produced in the human GI tract by Paneth cells. These enzymes are able to catalyze the hydrolysis of murein on the bacterial cell wall, providing effective protection against Gram-positive infection (Fleming 1922) . The human cathelicidin, LL-37, is also expressed by intestinal epithelial cells (Hase et al. 2002 (Hase et al. , 2003 Tollin et al. 2003) and, like the other AMPs, is involved in microbial homeostasis within the GI tract. As an example, Iimura et al. (2005) have found that the intestinal epithelium of mice lacking the murine homolog of human LL-37 exhibits high susceptibility to colonization by the lumen microbiota. In addition, in the gastric epithelium, gastric epithelial cells infected with Helicobacter pylori appear to up-regulate the production of LL-37 (Hase et al. 2003) . Such regulation is inferred to be crucial for maintaining the balance between the host mucosal response and gastric pathogen survival mechanisms, which can cause a lifetime of chronic infection. On the other hand, evidence is available that the expression of LL-37 is downregulated in biopsies taken from Shigella-infected patients, particularly in early infection; this might contribute to the pathogenesis caused by the bacterium (Islam et al. 2001) Collectively, this first line of defense staged by epithelial cells operates in a coordinated fashion to maintain boundaries and homeostasis. Epithelial cells products, such as mucus, AMPs and the release of IgA, keep autochthonous bacterial communities under growth-expansion control. In addition, these epithelial cell products exert a direct effect against incoming pathogenic insults.
Coming closer: direct interaction with the intestinal epithelial cell
To overcome the primary line of host defense, many microbes have evolved strategies to counter this initial attack and gain access to the basolateral epithelial domain in which the immune cells reside. Microfold cells (M cells) are associated with the transepithelial vesicular trafficking of antigens and microorganisms, including pathogens and indigenous microbes, from the intestinal lumen into the underlying gut-associated lymphoid tissue (GALT). The structure of this specialized epithelial cell is quite distinct compared with the rest of the cells in the epithelium. M cells lack an apical rigid brush border and instead, the membrane surface elaborates micro-projections that facilitate efficient endocytosis and transcytosis of microorganisms. The basolateral side of the M cells is invaginated forming a large intra-epithelial "pocket" in which immune cells such as T and B lymphocytes and macrophages reside (Neutra and Kraehenbuhl 2003) .
Bacterial internalization into and translocation across the M cells triggers the generation of IgA within the basolateral space. Bacterial translocation across M cells also promotes the proliferation of antigen-specific B lymphoblasts that migrate throughout the blood stream to the intestinal mucosa, where differentiation into plasma cells occurs (Neutra and Kraehenbuhl 2003) . Based on infections carried out in ligated ileal loops in rabbits and in monkeys, M cells represent a major entry site of Shigella flexneri at early stages of infection (Sansonetti et al. 1996) . Once S. flexneri gains access to the basolateral domain, this organism is able to infect the intestinal epithelium prompting an intense inflammatory reaction manifested clinically as the passage of bloody diarrhea. Evidence has also been presented that M cells are a major entry site of S. typhimurium (Jones et al. 1994; Marchetti et al. 2004) , Yersinia enterocolitica and Yersinia pseudotuberculosis (Grutzkau et al. 1990; Marra and Isberg 1997) .
However, given the vast epithelial surface area relative to the M cell surface area in the human large intestine (far less than 1%), other mechanisms allowing access to the basolateral membrane domain most probably exist (Perdomo et al. 1994) . We have proposed that S. flexneri alters the intestinal barrier function, specifically the tight junctional complex (TJC), which in turn facilitates the paracellular passage of the organism through the intestinal epithelial barrier (Sakaguchi et al. 2002) . The TJC is a specialized membrane domain at the most apical region of polarized epithelial cells. Together, the tight junction proteins, claudins and occludins form the major structural component of the tight junctional strands that seal the intercellular space and delineate apical from basolateral domains. The claudins (Furuse et al. 1998 ) and occludins (Furuse et al. 1993; Ando-Akatsuka et al. 1996) interact with the PDZ domains of the zonula occludens proteins ZO-1 and ZO-2 (Furuse et al. 1994; Itoh et al. 1999) , which bind directly to actin filaments at their COOHterminal regions, enabling them to function as cross-linkers between tight junction strands and actin filaments (Wittchen et al. 1999; Fanning et al. 1998; Itoh et al. 1999) . The breakdown of TJC integrity occurs in response to bacterial products such as Clostridium perfringens enterotoxin (Sonoda et al. 1999) , cytotoxic necrotizing factor 1 from E. coli (Oswald et al. 1994) , Clostridium difficile toxins (Nusrat et al. 1995; Nusrat et al. 2001) , Bordetella dermonecrotic toxin (Horiguchi et al. 1995) and zonula occludens toxin from Vibrio cholerae (Fasano et al. 2000) . The invasion of intestinal epithelial cells by Salmonella typhi can also disturb the TJC seal (Chen et al. 1996) , whereas enteropathogenic E. coli de-phosphorylate and dissociate occludin from TJC (Simonovic et al. 2000) .
The intestinal epithelium has also evolved receptors, such as the extracellular Toll-like receptors (TLRs) and the intracellular Nod-like receptors, to identify pathogens or pathogen-associated molecular patterns (PAMPs) that have breached the epithelial barrier by the recognition of conserved microbial elements such as flagellin, peptidoglycan, lipopolysaccharide (LPS) and formylated peptides. In general, upon specific microbial recognition, these receptors recruit adaptor proteins, such as MyD88, TRIF, TIRAP, TRAM and Rip2, which elicit the activation of signaling cascades that regulate the expression of nuclear factor kappa-B (NF-κB), mitogen-activated protein kinases (MAPK), or caspase-dependent signaling pathways. This activation induces the expression of pro-inflammatory and antimicrobial mediators, including interleukin (IL)-6, tumor necrosis factor alpha (TNF-α) and IL-1β (Kawai and Akira 2006) .
In particular, TLRs represent a conventional pattern recognition system of innate immunity with the remarkable ability to discriminate between distinct variant microbial structures/molecules from self (microbiota or commensal bacteria) and non-self, pathogenic microbes (Takeda et al. 2003) . Thus, these receptors are able to orchestrate the production of inflammatory cytokines, chemotactic factors and antimicrobial products in response to certain intestinal cues (Bogunovic et al. 2007; Cario and Podolsky 2000; Abreu et al. 2001) . To date, at least 11 TLR human homologs have been identified. The molecular structure of TLRs comprises three domains: (1) the extracellular domain, which exhibits a repeated leucine-rich motif, (2) the transmembranal domain and (3) the globular domain or Toll/IL-1 receptor domain localized within the cytoplasm. In addition, the location of each TLR on the extracellular cell surface determines ligand specificity and accessibility.
TLR4 is one of the best-studied TLRs. This receptor is crucial for the recognition of LPS, a major component of the outer membrane of Gram-negative bacteria. Indeed, lack of response to the LPS challenge has been associated with tlr4 gene mutations or deletions (Hoshino et al. 1999; Poltorak et al. 1998; Qureshi et al. 1999) . TLR4 is located at the apical pole of differentiated intestinal epithelial cells.
However, in vitro challenge of intestinal cell lines with LPS has been shown to promote TLR4 redistribution. For example, Cario et al. (2002) have demonstrated that the trafficking of TLR4 via transcytosis to the basolateral domain occurs following LPS-basolateral stimulation of differentiated T84 cells. Whereas the role of TLR4 on the basolateral domain remains to be determined, one study has revealed this receptor to be located at the epithelial basolateral domain during active ulcerative colitis (Cario and Podolsky 2000) . Conversely, TLR5 is constitutively expressed at the basolateral domain of the intestinal epithelium and recognizes bacterial flagella. In this location, TLR5 serves as a molecular beacon by providing a mechanism in which only those microbes that invade or translocate flagellin, such as S. typhimurium but not commensal bacteria, induce intestinal epithelia to orchestrate an inflammatory response (Lyons et al. 2004; Gewirtz et al. 2001) .
Additionally, the intracellular and surface expression of TLR9 has been detected in the intestinal cell line (HT-29). TLR9, which recognizes bacterial/viral DNA and unmethylated CpG dideoxynucleotides, has been associated with the proliferation of B cells and the activation of macrophages and dendritic cells (Hemmi et al. 2000) . Moreover, HT-29 cells infected with DNA from Salmonella enterica serovar Dublin exhibit an increased expression of TLR9 at the cell surface (Ewaschuk et al. 2007 ). Thus, the polarized but not static distribution, of TLRs on the intestinal epithelium seems to be governed by microbial stimulation, supporting the sentinel role of TLRs in GI mucosal immunity.
The intracellular recognition of PAMPs is facilitated by NOD-like receptors (NLRs). The NLRs possess a proteinprotein interaction domain at the N-terminus; this is commonly composed of a caspase recruitment domain (CARD) or pyrin domain (PYD). The CARD and PYD domains represent essential elements of protein recognition critical for downstream signaling and are both involved in apoptosis and inflammation. NLRs also contain a nucleotide-binding oligomerization domain (NOD) that establishes self-oligomerization during NLR activation and a C-terminal leucine-rich repeat for PAMPs recognition.
The best-characterized NLRs are NOD1 and NOD2, both of which represent pattern recognition receptors that identify different structural core motifs derived from peptidoglycan, a main constituent of bacterial cell walls. NOD1 is ubiquitously expressed by intestinal epithelial cells, whereas only monocytes, macrophages, dendritic cells and intestinal Paneth cells express NOD2. These two NLRs interact with an adaptor protein (Rip2), subsequently promoting the activation of the NF-κB and MAPK pathways (Girardin et al. 2001; Pauleau and Murray 2003) .
Bacteria equipped with secretion systems, such as Samonella and Helicobacter, or those that produce pore-forming toxins, such as the pneumolysin of Streptococcus pneumoniae, the anthrolysin O of Bacillus anthracis, or the α-toxin of Staphylococcus aureus, can promote the internalization of peptidoglycan fragments from extracellular bacteria into the cytoplasm of epithelial cells, thus activating intracellular NOD receptors. Alternatively, a human oligopeptide transporter (hPepT1), which is expressed in inflamed but not in non-inflamed colonic epithelial cells, can carry out the transport of bacterial derivates, such as N-formylated tripeptide N-formylmethionylleucyl-phenylalanine (fMLP) produced by E. coli and muramyl-dipeptides from the bacterial cell wall, into the cytosol of colonic epithelial cells; this might elicit the host immune response via NOD-like receptors recognition (Vavricka et al. 2004; Merlin et al. 2001; Charrier and Merlin 2006) . In addition, NOD1/2 can be recruited to the plasma-cell membrane from its intracellular localization, allowing a third method of NODdependent immune response activation (Barnich et al. 2005; Kufer et al. 2008) .
NOD2 is also known as the CARD receptor 15 (CARD15) and is highly expressed in Paneth cells; its stimulation promotes the activation of NF-κB and production of α-defensins. In addition, evidence exists for the role of NOD2 as an antibacterial modulator that restricts Salmonella proliferation in the intestinal epithelial cells (Hisamatsu et al. 2003) . Mutations in NOD2 also lead to significant deficiency of HD5 and HD6; this has been associated with ileal CrD (Wehkamp et al. 2005; Nuding et al. 2007 ) and chronic inflammation in IBD (Arijs et al. 2009 ). In a landmark study, Ogura et al. (2001) determined the association between frame-shift mutations of the nod2 gene and patients with CrD. Indeed, one of the models proposed for the development of CrD suggests that mutations in NOD2 might alter the mucosal host-microbial interactions through the modulation of α-defensins expression and are thus a risk factor for the disease (Cho 2008) . Moreover, Biswas and colleagues (2010) have discovered that NOD2-deficient mice develop a Th1-depedent granulomatous inflammation of the ileum when infected with Helicobacter hepaticus.
Recent studies have also revealed the involvement of NOD2 expression in the homeostasis of the intestinal microbiota. As an example, Petnicki-Ocwieja et al. (2009) have found that (1) NOD2 expression is activated by normal microbiota and that germ-free mice express significantly fewer receptors than wild-type mice; (2) the NOD2-deficient mouse harbors an increased load of indigenous resident bacteria in its intestine and that this phenomenon is independent of Rip2 expression; and (3) NOD2-deficient mice are less able to eradicate pathogens. Therefore, functional NOD2 appears to restrict chronic intestinal inflammation and in a feedback fashion, NOD2 and indigenous microbiota maintain the balance in the intestine by restricting the establishment of pathogens.
Concluding remarks
A representation of the role of epithelial cells in the immunity of the intestinal mucosal is presented in Fig. 1 . We have highlighted the main functions of intestinal epithelial cells in their various roles as a mucosal barrier and in innate mucosal immunity. The intestinal epithelium represents the first line of defense and is sufficiently equipped and finely tuned to face frequent challenges from self and non-self, transient and resident microorganisms. However, this intestinal barrier also co-evolved with normal and pathogenic flora. Thus, a diverse mucosal immune response exists to maintain a homeostatic host-commensal balance, to signal when such boundaries have been disrupted, and to respond appropriately to pathogenic insult or injury during disease.
